OncoSec Medical Appoints Engineering Leader Company expands engineering team to accelerate development of its proprietary cancer therapeutic delivery device
SAN DIEGO, July 5, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today the appointment of Brian McCluskey as Executive Director, Engineering, who will lead the development of the company's proprietary electroporation delivery technology, the OncoSec Medical System (OMS).
Punit Dhillon, OncoSec's President and CEO, said, "We are pleased that Brian will join our management team. He brings a proven track record of medical device design and technical leadership experience, with the ability to design, manage and coordinate the development of medical devices from concept to production. Brian will be instrumental in developing OncoSec's next generation OMS products."
OncoSec's minimally invasive ElectroOncology therapies utilize its proprietary electroporation delivery system, called the OncoSec Medical System (OMS), which applies short electrical impulses to selectively targeted tumors and tissue in order to significantly increase the ability of anti-cancer chemotherapeutic or biologic agents to enter into cells. These treatments selectively destroy cancer cells while preserving healthy tissue. They optimize required dosage and potentially reduce treatment and post-treatment costs.
Brian McCluskey, Executive Director, Engineering
Mr. McCluskey has more than 30 years of electrical engineering experience, in which he has spent the last 20 years developing software and hardware for devices used for medical and research purposes. Through this, he has managed successful submissions for FDA 510(k) approvals, as well as, CE marks for marketing in Europe. Mr. McCluskey was recently with Teledyne RD Instruments (TRDI), a leader in the design and manufacture of Doppler instrumentation, for which he managed custom production for TRDI clients. He was also engineering manager for Digirad Corporation, a leading manufacturer of solid-state gamma cameras and cardiology imaging software, for which he managed product development from early conception to product release leading to multi-million dollar revenue in his first year.
Mr. McCluskey will lead OncoSec's team of engineers and manufacturing operations as well as work closely with the company's Quality Assurance department.
About OncoSec Medical Inc.
OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Inc.